Human monocyte‐derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I‐restricted exogenous peptides
- 1 August 1997
- journal article
- Published by Wiley in Immunology
- Vol. 91 (4) , 635-642
Abstract
Recent experimental data have shown that mice could be immunized efficiently, in particular against cancer, by the injection of antigen‐loaded dendritic cells (DC) or macrophages (MPH). In the present work, these two antigen‐presenting cells (APC) were prepared in humans from circulating mononuclear cells (MNC). MPH were obtained from MNC that were cultured in hydrophobic plastic bags and purified by elutriation. DC were from the culture of adherent elutriation‐purified monocytes in the presence of granulocyte–macrophage colony‐stimulating factor (GM‐CSF) and interleukin‐4 (IL‐4). The two APC were prepared in parallel from the same donors and their phenotype and antigen‐presenting capacity were compared. DC differed from MPH by a higher expression of HLA‐DR and CD23 and a lower expression of CD14, CD64 and of adhesion molecules. DC and MPH were comparably effective in (a) enhancing the mitotic response of autologous lymphocytes to immobilized anti‐CD3 (accessory function); (b) presenting melanoma peptides to specific cytotoxic T lymphocyte (CTL) clones; and (c) stimulating the generation of CTL directed against a myxovirus influenza peptide. However, DC were more effective than MPH in inducing the mitotic response of allogeneic peripheral blood leucocytes (PBL), possibly because of their higher expression of HLA class II molecules. In conclusion, DC and MPH prepared from blood MNC did not differ substantially in their ability to activate HLA class I‐restricted T‐cell responses by exogenous peptide presentation.Keywords
This publication has 35 references indexed in Scilit:
- Dendritic cells: from ontogenetic orphans to myelomonocytic descendantsImmunology Today, 1996
- Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.Journal of Experimental Medicine, 1996
- Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.Journal of Experimental Medicine, 1996
- Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.Journal of Experimental Medicine, 1996
- Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.Journal of Experimental Medicine, 1996
- Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.Journal of Clinical Investigation, 1994
- Understanding the dendritic cell lineage through a study of cytokine receptors.Journal of Experimental Medicine, 1994
- Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell LinesScience, 1994
- GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cellsNature, 1992
- Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cellsCancer Immunology, Immunotherapy, 1992